ORIGINAL RESEARCH article
Front. Cell. Infect. Microbiol.
Sec. Clinical Infectious Diseases
Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1582843
This article is part of the Research TopicAdvances in Gut Microbiota, Metabolites and the Metabolic DisordersView all articles
Helicobacter pylori Infection and Apolipoprotein B/Apolipoprotein A1 Ratio: A Cross - Sectional Study
Provisionally accepted- 1Department of Endocrinology and Metabolism, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, Liaoning Province, China
- 2Department of Geriatrics, Shanghai Health and Medical Center, Wuxi, Liaoning Province, China
- 3Department of Surgery, Shanghai Health and Medical Center, Wuxi, Liaoning Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Helicobacter pylori (HP) infection is one of the most common chronic infections worldwide, closely related to various gastrointestinal diseases and metabolic disorders. In recent years, the relationship between HP infection and abnormal glucose and lipid metabolism has received significant attention, although its specific mechanisms remain unclear. This study aims to explore the association between HP infection and lipid metabolism abnormalities, particularly the role of the apolipoprotein B/A1 (ApoB/ApoA1) ratio.Methods: This cross-sectional study retrospectively analyzed data from 9,218 patients who underwent physical examinations at Shanghai Health and Medical Center in 2022. HP infection status was determined using the carbon-13 breath test, and clinical data, biochemical indicators, and lipid metabolism-related data were collected. Multiple regression analysis was employed to investigate the relationship between HP infection and the ApoB/ApoA1 ratio.Results: Patients in the HP-positive group were older and had a higher proportion of males. Their body mass index (BMI), blood pressure, γ-glutamyl transpeptidase (γ-GT), total cholesterol (TC), fasting blood glucose (FBG), Creatinine and White blood Cell were significantly higher than those in the HP-negative group. The HP-positive group exhibited a higher prevalence of underlying diseases (e.g., hypertension, diabetes, coronary heart disease) and significant abnormalities in glucose and lipid metabolism, uric acid, high-sensitivity C-reactive protein (hs-CRP), and other indicators. The ApoB/ApoA1 ratio was significantly elevated in the HP-positive group and was not influenced by gender. Multiple regression analysis revealed that the ApoB/ApoA1 ratio is an independent risk factor for HP infection.Conclusion: HP infection is closely associated with abnormal lipid metabolism, and the ApoB/ApoA1 ratio is an independent risk factor for HP infection, demonstrating significant advantages over other lipid indicators. This large-scale study highlights a significant association between HP infection and an elevated ApoB/ApoA1 ratio. The findings suggest that HP may contribute to cardiovascular risk via dyslipidemia, with the ApoB/ApoA1 ratio serving as a potential biomarker. Further research should explore whether HP eradication could mitigate these metabolic disturbances.
Keywords: Helicobacter pylori, Lipid metabolism abnormalities, ApoB/ApoA1 ratio, Crosssectional studies, cardiovascular disease
Received: 27 Feb 2025; Accepted: 23 Apr 2025.
Copyright: © 2025 Liu, Zhu, Pu, Zou, Zhou and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Lu Zhou, Department of Surgery, Shanghai Health and Medical Center, Wuxi, Liaoning Province, China
Xiaowei Zhu, Department of Endocrinology and Metabolism, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, Liaoning Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.